Dimethylfumarate impairs melanoma growth and metastasis

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11888-11896

  Loewe, Robert ^a   Valero, Teresa ^a   Kremling, Silvia ^a   Pratscher, Barbara ^a   Kunstfeld, Rainer ^a   Pehamberger, Hubert ^a   Petzelbauer, Peter ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLFUMARATE; FUMARIC ACID DERIVATIVE; KI 67 ANTIGEN; LIPOCORTIN 5; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GENE CONTROL; GENE MAPPING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; FEMALE; FUMARATES; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33846253614     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2397     Document Type: Article

References (45)

1. Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-κB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005;106:3940-7.
2. Munshi A, Kurland JF, Nishikawa T, et al. Inhibition of constitutively activated nuclear factor-κ radiosensitizes human melanoma cells. Mol Cancer Ther 2004;3:985-92.
3. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet HJ, Jr., Sledge GW, Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
4. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18:7389-94.
5. Yang JM, Richmond A. Constitutive IκB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res 2001;61:4901-9.
6. Hagemann T, Wilson J, Kulbe H, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J Immunol 2005;175:1197-205.
7. Aggarwal BB. Nuclear factor-κ-B: the enemy within. Cancer Cell 2004;6:203-8.
8. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-81.
9. Biswas DK, Shi Q, Baily S, et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42.
10. Yemelyanov A, Gasparian A, Lindholm P, et al. Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006;25:387-98.
11. 2-M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004;14:165-71.
12. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6:2573-81.
13. Stathopoulos GT, Zhu Z, Everhart MB, et al. Nuclear factor-κB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006;34:142-50.
14. Ohsugi T, Horie R, Kumasaka T, et al. In vivo antitumor activity of the NF-κB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005;26:1382-8.
15. Watanabe M, Dewan MZ, Okamura T, et al. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005;114:32-8.
16. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin Suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-8.
17. Richmond A. Nf-κB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002;2:664-74.
18. Bharti AC, Aggarwal BB. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8.
19. Orlowski RZ, Baldwin AS, Jr. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
20. Vandermeeren M, Janssens S, Wouters H, et al. Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-κB1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 2001;116:124-30.
21. Loewe R, Pillinger M, de Martin R, et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-κB-dependent manner. J Invest Dermatol 2001;117:1363-8.
22. Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-κB/p65 in human endothelial cells. J Immunol 2002;168:4781-7.
23. Schupp N, Schinzel R, Heidland A, Stopper H. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann N Y Acad Sci 2005;1043:685-95.
24. Wierinckx A, Breve J, Mercier D, et al. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005;166:132-43.
25. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005;104:879-90.
26. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365;687-701.
27. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA. Suppression of spontaneous melanoma metastasis in Scid mice with an antibody to the epidermal growth-factor receptor. Cancer Res 1991;51:2193-8.
28. Kunstfeld R, Wickenhauser G, Michaelis U, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003;120:476-82.
29. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-93.
30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
31. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol 2003;224:149-57.
32. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998;273:12584-92.
33. Merighi S, Benini A, Mirandola P, et al. A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem 2005;280:19516-26.
34. Emdad L, Sarkar D, Su Zz, et al. Activation of the nuclear factor κB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res 2006;66:1509-16.
35. Harant H, de Martin R, Andrew PJ, et al. Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic
36. acid and tumor necrosis factor-α involves the transcription factor NF-κB. J Biol Chem 1996;271:26954-61.
37. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431-42.
38. Shishodia S, Aggarwal BB. Nuclear factor-κB: a friend or a foe in cancer? Biochem Pharmacol 2004;68:1071-80.
39. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005;11:43-8.
40. Burch PM, Heintz NH. Redox regulation of cell-cycle re-entry: cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species. Antioxid Redox Signal 2005;7:741-51.
41. BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative-Fumapharm/Biegen Idec. Drugs R D 2005;6:229-30.
42. Hoefhagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149:363-9.
43. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
44. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
45. Lev DC, Ruiz M, Mills L, et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2:753-63.